Expression and clinical significance of lncRNA SNHG3 in peripheral blood mononuclear cells of patients with chronic obstructive pulmonary disease
2020-04-03JianGuangXuJieZhaoYiXiuYangFeiChenLiangHuangXiuKuanLiDuoJianGuoJuanSunXiaoManZhouJianFangLiuQiongFengHuiFangShiYiPengDing
Jian-Guang Xu, Jie Zhao, Yi-Xiu Yang, Fei Chen, Liang Huang, Xiu-Kuan Li, Duo-Jian Guo, Juan Sun, Xiao-Man Zhou, Jian-Fang Liu, Qiong Feng, Hui-Fang Shi, Yi-Peng Ding
1. Department of Respiratory Medicine, The Second Affiliated Hospital of Hainan Medical University
2. Hainan Hospital Affiliated to Nanhua University
3. Department of General Medicine, Hainan Hospital Affiliated to Hainan Medical University
4. Department of General Medicine, Hainan General Hospital
5. Health center of Wencheng town, Wenchang City
6. Xincun Health center of Lingshui Li Autonomous County
7. Meitai Health center of Lingao County
8. Zuguan Health center of Lingshui Li Autonomous County, Haikou 570311
Keywords:
ABSTRACT
1. Introduction
Chronic obstructive pulmonary disease (COPD) is a disease that can be prevented and treated with incomplete reversible airflow limitation and progressive development, and the lungs are harmful to harmful gases such as cigarette smoke or harmful particles.Abnormal inflammatory response is related [1-3]. COPD mainly affects the lungs, but can also cause systemic (or extrapulmonary)adverse effects. Although COPD is a disease that can be treated and prevented, the incidence continues to rise due to the global prevalence of smoking and some damage to the human body, such as indoor and outdoor air pollution, biofuels, and occupational dust[4]. Long noncoding RNA (lncRNA), a nucleic acid sequence with a transcription length of more than 200 bp, is considered to have no protein coding function. Current research shows that lncRNA plays an important role in regulating cell proliferation, apoptosis,invasion and angiogenesis [5-7]. As the incidence of lung diseases increases year by year, the molecular biology of lung diseases has become more and more intensive, and the discovery of lncRNA has undoubtedly opened a new direction for molecular diagnosis and gene therapy of diseases. This study examined the expression of lncRNA SNHG3 in peripheral blood mononuclear cells from patients with COPD, explored its expression and the clinical significance of COPD disease, and sought new molecular targets for the treatment and diagnosis of COPD.
2. Materials and methods
2.1 General information
In this study, the COPD group and the control group were from Hainan Provincial People's Hospital, of which 110 healthy control groups were from physical examination, and their age and gender matched the COPD group. The COPD group came from patients treated at Hainan Provincial People's Hospital from May 2015 to August 2017, and was judged as COPD according to the guidelines for diagnosis and treatment of chronic obstructive pulmonary disease[5]. The COPD group was classified according to pulmonary function tests: FEV1 as a percentage of the expected value FEV1% expected value) ≥ 80% is mild (n = 40), 50% ≤ FEV1% expected value<80% is moderate (n = 25), 30% ≤ FEV1% expected value <50%is severe ( n = 30), FEV1% predicted value <30% is extremely severe (n = 25). This study was approved by the Ethics Committee of Hainan Provincial People's Hospital. There were no significant differences in gender group words, mean age, BMI, and smoking rate markers between the two groups of patients (P <0.05, see Table 1), which are comparable.
Lymphocyte isolation solution was purchased from sigma company, total RNA extraction kit and reverse transcription kit were purchased from Tiangen company. Primer design and synthesis were synthesized by Shanghai Shenggong. GAPDH upstream primer sequence: TGACTTCAACAGCGACACCCA, downstream primer sequence: CACCCTGTTGCTGTAGCCAAA.
2.2 Experimental methods
2.2.1 Mononuclear cell collection
Collect fresh whole blood and add an equal volume of PBS, mix thoroughly; transfer to a lymphocyte separation tube, centrifuge at 3000C for 30 min at 20 C; use a pipette to separate the white blood cell layer, add 20 times the volume of TRIzol reagent for leukocytes.Repeatedly beat the cells with a disposable syringe until no clumps of cells are visible. The entire solution is clear and not sticky, and stored in a -80 C refrigerator.
2.2.2 RT-PCR detection and detection of mononuclear cells
Total RNA extraction kits from Tiangen were used to extract total RNA and reverse transcribed into cDNA. Then SNHG3-specific upstream primers were designed and tested by RT-PCR. GAPDH was used as an internal reference. The amount of expression.
2.2.3 Starbase database
The database (http://starbase.sysu.edu.cn/index.php) is used to predict that SNHG3 and mir-186 have binding sites, design SNHG3 mutant sequences, and construct them into the double luciferase vector 3 ' On the UTR end, wild-type and mutant-type and mir-181 or unloaded control were transfected into cells with lipo3000,respectively, and the expression of firefly fluorescence and Renilla fluorescence were detected using a microplate reader and statistically analyzed. Repeat for three replicates in each group.
2.2.4 Calculation
The numerical calculation uses the mean plus or minus the standard deviation expression, SPSS 17.0 statistical software is used to analyze the variance between the two groups, using the t test, P<0.05 is considered to have a statistically significant difference.
3. Results
3.1 SNHG3 expression in peripheral blood mononuclear cells of patients with COPD
The relative expression of SNHG3 in peripheral blood mononuclear cells of the COPD group was 1.52 ± 0.52, which was lower than the normal control group of 2.51 ± 0.59 (t = 13.55, P <0.001), as shown in Figure 1.

Table1 Comparison of general information between two groups of patients

Figure 1: Relative expression of SNHG3 in peripheral blood mononuclear cells between COPD and normal controls
3.2 SNHG3 expression in peripheral blood mononuclear cells of patients with COPD and lung function.
Relative expression of SNHG3 in peripheral blood mononuclear cells of mild lung group was 2.16 ± 0.23, which was higher than that of moderate group 1.55 ± 0.10 (t = 12.32, P <0.001), and severe group 1.19 ± 0.11 (t = 21.12, P <0.001 ), And extremely severe group 0.89 ± 0.06 (t = 26.63, P <0.001), as shown in Figure 2.

Figure 2: Relative expression of SNHG3 in different lung function groups in patients with COPD
3.3 Prediction of miRNAs that SNHG3 may bind and verification of dual luciferase
SNHG3 was predicted to bind to mir-186 from the starbase database (Figure 3A). The luciferase activity was detected by double luciferase. The relative overexpression of the SNHG3 wild type and the mir-186 group (SNHG3 wild type + mir-186) and the mir-186 group (overexpression empty load + mir-186) were significantly Inhibition (t = 4.387, P <0.05). At the same time, the SNHG3 wild type and mir-186 group (SNHG3 wild type + mir-186) were significantly inhibited relative to the SNHG3 mutation and the mir-186 group (SNHG3 mutation + mir-186) (t = 5.735, P <0.05), as shown in Figure 3

Figure 3: SNHG3 and mir-186 binding site prediction and dual luciferase assay validation. A: The Starbase database predicts the binding site of SNHG3 to mir-181 and the designed mutant sequence. B: Dual luciferase assay verified that SNHG3 binds to mir-181
4. Discussion
Chronic Obstructive Pulmonary Disease (COPD) is a slow-moving respiratory disease. Its growth and development are the result of the interaction between multiple inflammatory cells, and the persistent airflow limitation is not completely reversible as Its main features[9]. The morbidity and mortality of COPD are increasing year by year globally. The reasons include increasing social aging, large number of smokers, increasing air pollution, and occupational exposure without protective measures [10]. The epidemiological survey report on COPD in China shows that the probability of COPD among adults aged 20 years and over is 8.6%. As the age increases, the prevalence of COPD is higher, and the prevalence of COPD is over 13.7%. The prevalence of people over 60 years of age is more than 27%, of which the number of male patients is 2.2 times that of female patients [11]. Based on this, it is estimated that the prevalence of COPD nationwide is nearly 100 million people.Due to the numerous risk factors such as environmental pollution and high smoking rate, residents and medical personnel generally lack awareness and preventive measures are not in place. The COPD mortality rate in China accounts for 31.1% of the global COPD deaths [12]. At present, there is still a lack of rapid and effective diagnostic and treatment methods for COPD, and how to effectively prevent and treat COPD has become the focus of research in the medical community in recent years. Therefore, finding effective and convenient molecular targets for the prevention and treatment of COPD is an urgent problem and research hotspot for medical workers and scientific researchers.
Long non-coding RNA (long non-coding RNA, lncRNA) is a type of RNAs whose transcripts are longer than 200 nt and do not encode proteins. Compared with miRNA, lncRNA has a longer sequence and more complicated spatial structure, and the mechanisms involved in expression regulation are more diverse and complicated. It has been found that lncRNA can regulate gene expression at epigenetic[13-15], transcription [16-18] and post-transcription [19-21] levels, and participate in development, differentiation, metabolism, genomic imprinting, and chromatin modification and transcription. Many important regulatory processes, such as activation and inhibition,and nuclear transport, are closely related to the occurrence and development of disease. In this study, we found that the expression level of lncRNA SNHG3 in peripheral blood mononuclear cells of patients with COPD (1.52 ± 0.52) was significantly lower than that of the normal control group (2.51 ± 0.59, t = 13.55, P <0.001), and the lung function was light. The relative expression of SNHG3 in peripheral blood mononuclear cells in the moderate group was 2.16± 0.23, which was significantly higher than that in the moderate group (1.55 ± 0.10 (t = 12.32, P <0.001), and the severe group 1.19± 0.11 (t = 21.12, P <0.001), And extremely severe group 0.89 ±0.06 (t = 26.63, P <0.001). These results indicate that low expression of lncRNA SNHG3 in peripheral blood mononuclear cells in patients with COPD may be a risk factor for COPD and may be one of the indicators of the severity of COPD patients.
Recent studies have shown that lncRNAs can be used as competitive endogenous RNAs (ceRNAs) to participate in regulating multiple biological functions of cells. Studies have shown that ceRNA activation depends on miRNA / ceRNA imbalance, and ceRNA is closely related to miRNA, RNA editing, and RNA binding proteins[22, 23]. In this study, we found that lncRNA SNHG3 can target and regulate miR-186 expression in peripheral blood mononuclear cells of patients with COPD, which indicates that the lncRNA SNHG3/ miR-186 regulatory network may play an important role in the occurrence and development of COPD.
杂志排行
Journal of Hainan Medical College的其它文章
- Meta analysis and medication analysis of TCM compound in the treatment of senile osteoporosis
- The Effect of Clinically Used Crystalloid Solution on the Clearance Rate of Lactic Acid in Septic Shock Patients
- Efficacy of intravitreal injection of ranibizumab in the treatment of macular edema secondary to non-ischemic branch retinal vein occlusion
- Efficacy of PC-PRL implantation in the treatment of high myopia and its complications
- Clinical study of warm acupuncture combined with massage in treatment of periathritis of shoulder
- Effects of Pioglitazone on Renal Mitochondrial calcium and cytochrome C levels in Early Diabetic Nephropathy Rats
